In mice, shutting down hypocretin/orexin-1 signaling reduced intravenous self-administration of a synthetic cannabinoid and eliminated THC-evoked dopamine increases in the nucleus accumbens.
Readers tracking potential medication targets for cannabis use disorder, addiction neuroscientists interested in orexin circuitry, and anyone parsing how cannabinoid reward shows up in rodent models.
No NAc dopamine riseafter THC in orexin-1 knockout mice, indicating disrupted reward signaling in this model
What the researchers found
Two complementary approaches pointed to the same result. Systemic dosing with SB334867, an orexin-1 receptor (Hcrtr-1) antagonist, reduced how often mice self-administered WIN55,212-2, a synthetic cannabinoid, and lowered the maximum effort they would expend for an infusion under a progressive ratio schedule. Mice genetically lacking Hcrtr-1 showed a similar reduction in reinforcing and motivational measures, reinforcing the pharmacology result.
Activation mapping aligned with behavior. Contingent, but not noncontingent, self-administration of WIN55,212-2 increased the fraction of lateral hypothalamic hypocretin neurons expressing FosB/ΔFosB, a marker of repeated neuronal activation linked to motivation. Finally, the dopamine signal that typically follows Δ9-THC in the nucleus accumbens did not appear in Hcrtr-1 knockout mice during microdialysis testing. Together, the data position Hcrtr-1 as a node in the cannabinoid reward pathway in mice.
Why it matters
There were no accepted medications for cannabis dependence when this study was published. The hypocretin/orexin system had been tied to reward and stress across several drug classes. This work placed orexin-1 in the cannabinoid reinforcement circuit in mice, identifying a preclinical target that could inform future translational research while underscoring the need to test whether the same circuitry matters outside this model.
The numbers in context
- Self-administration: reduced when mice received the orexin-1 antagonist SB334867 compared to vehicle
- Motivation: lower breakpoints under a progressive ratio schedule after Hcrtr-1 blockade, indicating less willingness to work for the drug
- Hypocretin neuron activation: increased FosB/ΔFosB in lateral hypothalamic hypocretin cells during contingent, not noncontingent, WIN55,212-2 intake
- Accumbens dopamine: THC-evoked extracellular dopamine rise was absent in Hcrtr-1 knockout mice
How the study worked
Researchers trained mice to self-administer the cannabinoid agonist WIN55,212-2 through an intravenous catheter, a standard operant model of drug reinforcement. They tested the effects of blocking hypocretin/orexin-1 with SB334867 and used Hcrtr-1 knockout mice to probe the same pathway genetically. Motivation was measured under progressive ratio schedules, where the required number of lever presses increases after each dose. To control for non-specific motor or learning effects, separate mice were trained to work for water. Neuronal activation in hypocretin neurons of the lateral hypothalamus was assessed with double-label immunofluorescence for FosB/ΔFosB and hypocretin-1. Lastly, in vivo microdialysis measured extracellular dopamine in the nucleus accumbens after acute THC. The abstract does not report sample sizes or drug doses. Mice were male per MeSH terms.
Who was studied
Mice, including Hcrtr-1 knockout mice, Country not specified
What this study cannot tell us
This is an animal study using a synthetic cannabinoid (WIN55,212-2) delivered intravenously, a route and compound that do not mirror typical human cannabis exposure. Only males were used per MeSH terms. The abstract reports no sample sizes or antagonist doses. SB334867 can show off-target effects at certain concentrations. Developmental compensation in Hcrtr-1 knockout mice could contribute to the phenotype. The operant control with water suggests general performance was intact, but sedation or arousal changes were not detailed. THC was only used for the dopamine microdialysis readout, not for self-administration.
How to read the evidence
Rated preliminary: well-controlled rodent work combining pharmacology, genetics, operant behavior, and microdialysis, but limited by species, use of a synthetic cannabinoid and intravenous route, male-only subjects, and absent sample size reporting.
When this study was published
Published in 2014. Since then, orexin antagonists entered clinical practice for insomnia, but whether orexin-1 blockade affects cannabis use in people remains an open question.
The bigger picture
Hypocretin/orexin neurons regulate arousal, stress, and reward. This study connects that system to cannabinoid reinforcement in mice using both pharmacology and genetics, plus converging behavioral and neurochemical readouts. It also intersects with a drug class already in clinical use for sleep, the dual orexin receptor antagonists, though this paper specifically targets orexin-1 and tests a synthetic cannabinoid delivered intravenously. That difference matters. WIN55,212-2 is not THC, and intravenous self-administration in mice is far from how people use cannabis. The dopamine finding ties orexin-1 to a classic reward pathway readout, but dopamine release in rodents does not map cleanly to human motivation or problem use.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would blocking orexin-1 alter self-administration of THC itself, not just a synthetic agonist, and across different routes of administration?
- Do dual orexin antagonists or selective orexin-2 blockade yield similar or opposite effects on cannabinoid reinforcement?
- How do orexin-1 manipulations affect relapse-like behaviors, such as cue- or stress-induced reinstatement in cannabinoid models?
- Are there dose ranges for orexin-1 antagonists that separate reward effects from sleep and arousal effects in rodents?
- Do female mice show the same pattern of changes in cannabinoid self-administration with orexin-1 blockade?
Common questions
Did blocking orexin-1 make mice stop working for all rewards?
Was this about THC?
Does this mean orexin drugs will treat cannabis dependence?
Read the original research
The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward.
Biological psychiatry, 75(6), 499-507
Biological Psychiatry is a reputable journal focusing on psychiatric neuroscience and therapeutics.
Citation
Flores, África; Maldonado, Rafael; Berrendero, Fernando. (2014). The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward.. Biological psychiatry, 75(6), 499-507. https://doi.org/10.1016/j.biopsych.2013.06.012
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit
- Why Does Weed Make You Laugh? THC and Humor Processing
- THC and Discipline: Does Daily Use Erode Willpower
- Cannabis and Parkinson's Disease: Tremor, Sleep, and Quality of Life